Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joep de Bruijne

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Expert Opinion on Investigational Drugs|December 1, 2011
Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis CPeter L M Jansen, Joep De Bruijne
Current Gastroenterology Reports|April 18, 2008
Novel therapies in hepatitis B and CBart Takkenberg, Joep de Bruijne, Christine Weegink, et al.
Journal of Viral Hepatitis|December 10, 2020
Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysisMyrte Gorris, Bernice M van der Lecq, Karel J van Erpecum, et al.
Antiviral Therapy|March 20, 2014
MicroRNAs: role and therapeutic targets in viral hepatitisMeike H van der Ree, Joep de Bruijne, Neeltje A Kootstra, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 8, 2012
[New class of medicines for chronic hepatitis C]Sem J Aronson, Joep de Bruijne, Janke Schinkel, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 6, 2011
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatmentJoep de Bruijne, James C Sullivan, Tara L Kieffer, et al.
Cardiovascular and Interventional Radiology|August 26, 2025
Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute ContraindicationNiek Wijnen, Emma Ruijs, Rutger C G Bruijnen, et al.
Cardiovascular and Interventional Radiology|September 13, 2023
Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor AblationMaarten L J Smits, Rutger C G Bruijnen, Philip Tetteroo, et al.
Clinics and Research in Hepatology and Gastroenterology|September 17, 2018
Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver diseaseMaria Cristina Leoni, Linde Amelung, Faydra I Lieveld, et al.
Cancers|January 28, 2026
Is There a Role for Hepatobiliary Scintigraphy in Thermal Ablation of Hepatocellular Carcinoma?Niek Wijnen, Joep de Bruijne, Rutger C G Bruijnen, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Expert Opinion on Investigational Drugs|December 1, 2011
Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis CPeter L M Jansen, Joep De Bruijne
Current Gastroenterology Reports|April 18, 2008
Novel therapies in hepatitis B and CBart Takkenberg, Joep de Bruijne, Christine Weegink, et al.
Journal of Viral Hepatitis|December 10, 2020
Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysisMyrte Gorris, Bernice M van der Lecq, Karel J van Erpecum, et al.
Antiviral Therapy|March 20, 2014
MicroRNAs: role and therapeutic targets in viral hepatitisMeike H van der Ree, Joep de Bruijne, Neeltje A Kootstra, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 8, 2012
[New class of medicines for chronic hepatitis C]Sem J Aronson, Joep de Bruijne, Janke Schinkel, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 6, 2011
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatmentJoep de Bruijne, James C Sullivan, Tara L Kieffer, et al.
Cardiovascular and Interventional Radiology|August 26, 2025
Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute ContraindicationNiek Wijnen, Emma Ruijs, Rutger C G Bruijnen, et al.
Cardiovascular and Interventional Radiology|September 13, 2023
Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor AblationMaarten L J Smits, Rutger C G Bruijnen, Philip Tetteroo, et al.
Clinics and Research in Hepatology and Gastroenterology|September 17, 2018
Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver diseaseMaria Cristina Leoni, Linde Amelung, Faydra I Lieveld, et al.
Cancers|January 28, 2026
Is There a Role for Hepatobiliary Scintigraphy in Thermal Ablation of Hepatocellular Carcinoma?Niek Wijnen, Joep de Bruijne, Rutger C G Bruijnen, et al.
Pageof 4